Your browser doesn't support javascript.
loading
High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay
Markus H Kainulainen; Eric Bergeron; Payel Chatterjee; Asheley P Chapman; Joo Lee; Asiya Chida; Xiaoling Tang; Rebekah E Wharton; Kristina B Mercer; Marla Petway; Harley M Jenks; Timothy D Flietstra; Amy J Schuh; Panayampalli S Satheshkumar; Jasmine M Chaitram; S Michele Owen; M G Finn; Jason M Goldstein; Joel M Montgomery; Christina F Spiropoulou.
Affiliation
  • Markus H Kainulainen; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Eric Bergeron; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Payel Chatterjee; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Asheley P Chapman; School of Chemistry and Biochemistry, School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA
  • Joo Lee; Reagent and Diagnostic Services Branch, Division of Scientific Resources, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Asiya Chida; Reagent and Diagnostic Services Branch, Division of Scientific Resources, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Xiaoling Tang; Reagent and Diagnostic Services Branch, Division of Scientific Resources, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Rebekah E Wharton; Emergency Response Branch, Division of Laboratory Sciences, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Kristina B Mercer; Newborn Screening & Molecular Biology Branch, Division of Laboratory Sciences, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Marla Petway; Reagent and Diagnostic Services Branch, Division of Scientific Resources, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Harley M Jenks; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Timothy D Flietstra; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Amy J Schuh; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Panayampalli S Satheshkumar; Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Jasmine M Chaitram; Division of Laboratory Systems, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • S Michele Owen; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • M G Finn; School of Chemistry and Biochemistry, School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA
  • Jason M Goldstein; Reagent and Diagnostic Services Branch, Division of Scientific Resources, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Joel M Montgomery; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
  • Christina F Spiropoulou; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, GA, USA
Preprint in English | medRxiv | ID: ppmedrxiv-20195446
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
SARS-CoV-2 emerged in late 2019 and has since spread around the world, causing a pandemic of the respiratory disease COVID-19. Detecting antibodies against the virus is an essential tool for tracking infections and developing vaccines. Such tests, primarily utilizing the enzyme-linked immunosorbent assay (ELISA) principle, can be either qualitative (reporting positive/negative results) or quantitative (reporting a value representing the quantity of specific antibodies). Quantitation is vital for determining stability or decline of antibody titers in convalescence, efficacy of different vaccination regimens, and detection of asymptomatic infections. Quantitation typically requires two-step ELISA testing, in which samples are first screened in a qualitative assay and positive samples are subsequently analyzed as a dilution series. To overcome the throughput limitations of this approach, we developed a simpler and faster system that is highly automatable and achieves quantitation in a single-dilution screening format with sensitivity and specificity comparable to those of ELISA.
License
cc0
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: Available Collection: Preprints Database: medRxiv Type of study: Diagnostic study / Qualitative research Language: English Year: 2020 Document type: Preprint
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: Available Collection: Preprints Database: medRxiv Type of study: Diagnostic study / Qualitative research Language: English Year: 2020 Document type: Preprint